Anjos Déborah, Fiaccadori Fabiola Souza, Servian Carolina do Prado, da Fonseca Simone Gonçalves, Guilarde Adriana Oliveira, Borges Moara Alves Santa Bárbara, Franco Fernanda Craveiro, Ribeiro Bergmann Morais, Souza Menira
Laboratório de Virologia e Cultivo Celular, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.
Laboratório de Imunorregulação, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.
J Clin Virol Plus. 2022 Feb;2(1):100059. doi: 10.1016/j.jcvp.2021.100059. Epub 2021 Dec 16.
COVID-19 pandemic continues to be a priority in public health worldwide, and factors inherent to SARS-CoV-2 pathogenesis and genomic characteristics are under study. Investigations that evaluate possible risk factors for infection, clinical manifestations, and viral shedding in different specimens also need to clarify possible associations with COVID-19 prognosis and disease outcomes.
In this study, we evaluated SARS-CoV-2 positivity and estimated viral loads by real-time RT-PCR in stool, sera, and urine samples from 35 patients, with a positive SARS-CoV-2 RNA molecular test in respiratory sample, attended at a University COVID-19 referral hospital in Goiania, Goias, Brazil. Whole-genome sequencing was also performed in samples with higher viral load.
The positivity index was 51.43%, 14.28%, and 5.71% in stool, sera, and urine specimens, respectively. The median viral load was 8.01 × 10 GC/g, 2.03 × 10 GC/mL, and 1.36 × 10 GC/mL in stool, sera, and urine, respectivelly. Of all patients, 88.57% had previous comorbidities, and 48.39% of them had detectable SARS-CoV-2 RNA in at least one type of clinical specimen evaluated by this study (stool, sera or urine). A higher viral load was observed in patients with more than two previous comorbidities and that were classified as severe or critical conditions. Samples with the highest viral loads were sequenced and characterized as B.1.1.33 variant.
We conclude that SARS-CoV-2 RNA is present in more than one type of clinical specimen during the infection, and that the most critical patients had detectable viral RNA in more than one clinical specimen at the same time point.
2019冠状病毒病(COVID-19)大流行仍是全球公共卫生领域的重点,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)发病机制和基因组特征的内在因素正在研究中。评估不同标本中感染、临床表现和病毒脱落的可能危险因素的调查,也需要阐明与COVID-19预后和疾病结局的可能关联。
在本研究中,我们对巴西戈亚斯州戈亚尼亚市一家大学COVID-19转诊医院收治的35例呼吸道样本SARS-CoV-2 RNA分子检测呈阳性的患者的粪便、血清和尿液样本,通过实时逆转录聚合酶链反应(RT-PCR)评估SARS-CoV-2阳性情况并估计病毒载量。对病毒载量较高的样本也进行了全基因组测序。
粪便、血清和尿液标本的阳性指数分别为51.43%、14.28%和5.71%。粪便、血清和尿液中的病毒载量中位数分别为8.01×10基因组拷贝数/克、2.03×10基因组拷贝数/毫升和1.36×10基因组拷贝数/毫升。所有患者中,88.57%有既往合并症,其中48.39%在本研究评估的至少一种临床标本(粪便、血清或尿液)中检测到SARS-CoV-2 RNA。既往合并症超过两种且被分类为重症或危重症的患者中观察到较高的病毒载量。对病毒载量最高的样本进行测序,并鉴定为B.1.1.33变异株。
我们得出结论,感染期间SARS-CoV-2 RNA存在于不止一种临床标本中,且病情最严重的患者在同一时间点的不止一种临床标本中检测到病毒RNA。